If you’ve been keeping a close eye on share tips 2025, then don’t miss this weekly round-up of the top stocks to consider for your portfolio.
The MoneyWeek share tips 2025 guide pulls together some of the best stocks from some of the top share tipsters around.
As well as the UK financial pages, we look at publications across the pond for investors who want to diversify their holdings internationally.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
We look at where to invest in 2025 – from big tech stocks and top funds to finding value in the FTSE 100.
This list is updated weekly.
Share tips 2025: top picks of the week
Four to buy
1. AstraZeneca (LSE: AZN)
The Telegraph
AstraZeneca’s shares slipped after the group’s first-quarter results, which showed revenue growth falling short of expectations. The fall was “unjustified” as the pharmaceutical giant is still on track to meet full-year guidance. AstraZeneca’s strong fundamentals, favourable long-term growth outlook and sound strategy mean it is well-placed to overcome uncertainties. 10,346p
2. RC Fornax (LSE: RCFX)
This is Money
The defence contractor counts some of the biggest names in defence as its clients. Its projects include helping with early-stage designs for RAF fighter jets, installing technology on tanks and developing submarine safety systems. Although RC is a small player in a £55 billion market dominated by multinationals, its “reputation as a pedigree operator” should prove beneficial as the Ministry of Defence expands its roster. 41p
3. InPost (AMS: INPST)
Shares
Luxembourg-based InPost is a rapidly growing e-commerce and fulfilment services platform. Analysts at Jefferies expect growth of 20% in adjusted earnings over the next five years, and the current “undemanding” valuation suggests investors are effectively getting the firm’s international business for free. First-quarter parcel volumes and margins rose. The UK and French operations are profitable, and InPost has a 70% share of the Polish market. It faces competition from Amazon, but its lack of a legacy delivery service is an advantage. €15.20
4. Trainline (LSE: TRN)
Investors’ Chronicle
Trainline’s full-year top-line growth was bolstered by a stronger domestic market. Yet, the ticketing platform’s stock is down 38% this year on reports of a state-backed rival potentially materialising. Changes in Google’s search system, favouring advertisers, have led Trainline to expect slower sales growth this year. Still, Trainline’s valuation is “too cheap” for a high-margin business that gives a lot of cash, while any rival will not appear before 2027. 274p
The rest...
1. Burberry (LSE: BRBY)
Investors’ Chronicle
Burberry’s first full-year results under new CEO Joshua Schulman were positively received. The luxury fashion house reported unexpectedly good fourth-quarter sales and profits while announcing new cost cuts. Retail sales fell 6%, but sales in China were improving by the year-end. Burberry aims to save £100 million by fiscal 2027, including cutting 1,700 jobs. No formal sales guidance was given, but Burberry aims to improve margins, productivity and cash flow. Schulman’s plan is still in the early stages. Hold (990p).
2. Gear4music (LSE: G4M)
Shares
Despite supply-chain difficulties and weak consumer confidence, Gear4music has returned to growth and reduced debt. The musical instruments retailer has a strong online presence in 190 countries, is a well-recognised brand with long-term relationships with major manufacturers and looks poised to profit from the recent insolvency of two competitors. Its shares peaked in 2021 during lockdown but have since lost 50%. Market-share gains and profit upgrades could give the stock a big fillip. Buy (165p).
3. Croda (LSE: CRDA)
The Telegraph
Croda develops ingredients for pharmaceutical, personal care, beauty, crop-care and industrial companies. Its profits and share price have been in a tailspin because its shares were overvalued at their peak, while demand for ingredients used in mRNA vaccines has fallen. Recent acquisitions and heavy investments, meanwhile, have hit returns and raised costs. Croda is focusing on product innovation and cost efficiencies, and its balance sheet is stable. While the dividend may not grow quickly, a 3.5% forward yield “may help investors stay patient”. Buy (3,140p).
This article was first published in MoneyWeek's magazine. Enjoy exclusive early access to news, opinion and analysis from our team of financial experts with a MoneyWeek subscription.
-
Shein shifts IPO focus to Hong KongThe development piles fresh pressure on London’s beleaguered stock market, which many had hoped would be boosted by Shein’s IPO
-
Scientists turn lead into gold – could it wreck the yellow metal's price?Medieval alchemists have been vindicated after scientists turned lead into gold, but the results aren’t going to crash the gold price any time soon
-
Trainline: a cheap cash machine for investorsOpinion Trainline’s shares have slumped owing to concerns about growth, but the sell-off seems overdone
-
Look to British stocks to lead the charge as the Magnificent Seven falterOpinion Gervais Williams, fund manager, The Diverse Income Trust, picks three British stocks where he'd put his money
-
'Technology will determine tomorrow’s top stocks in emerging markets'Opinion John Citron, investment manager of the JPMorgan Emerging Markets Investment Trust, tells us where he’d put his money
-
Three British mid-caps that could make 'attractive' investmentsOpinion Charles Luke, manager of the Murray Income Trust, highlights three UK-listed mid-cap companies, as he tells us where he'd put his money
-
LendInvest: a promising fintech firm going cheapOpinion LendInvest has made some mistakes in the past, but it’s now primed for growth, says Rupert Hargreaves
-
The star small and mid-cap stocks income investors have overlookedOpinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Chemring Group: an explosive investment opportunity in defenceEuropean states are raising their military spending, and Chemring Group looks well placed to profit
